Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).

5071Background: Management of HRPCa remains a clinical challenge. Novel AR inhibitors are now standard of care in castration-resistant prostate cancer (CRPC) and could potentially impact outcome in...